© 2018 Aston Sci. Inc. All rights reserved.
Aston Sci.'s press release archive.
SEOUL, South Korea--(BUSINESS WIRE)--Aston Sci., a portfolio model biopharmaceutical company, announced that the study results of its therapeutic cancer vaccine pipelines, AST-301 and AST-021p, will be presented at the Society for Immunotherapy of Cancer(SITC) in November. The respective abstract for AST-301 and AST-021p were accepted by the SITC.
The data from the study of AST-301, a pDNA-based cancer vaccine, using mice
models with HER2-expressing gastric cancer shows the efficacy of monotherapy
and combination therapy of the vaccine. At the 2021 American Society of
Clinical Oncology (ASCO) in June, Aston Sci. demonstrated the medical efficacy
and long-term safety of AST-301 through the results from phase 1 clinical
trials on 66 patients with HER2-positive advanced breast cancer. AST-301 is
currently under IND review by the Ministry of Food and Drug Safety for subsequent
clinical trials.
Aston Sci. also presents the efficacy of combination therapy of AST-021p using
a breast cancer mouse model. AST-021p is an investigational therapeutic cancer
vaccine composed of two different peptides which are derived from HLA class II
binding epitopes of human HSP90 protein. The results of comparative evaluation
on tumor growth inhibition and immunogenicity when used in combination with
several immune adjuvants, including “L-pampo™” (TLR-2/3 ligand-based immune adjuvant)
in-licensed from the CHA Vaccine Institute, will be presented. Currently,
AST-021p is in phase 1 clinical trial for recurrent or advanced solid tumors
for which there is no standard treatment.
“As cancer has become a disease requiring more prevention and management
due to technological advances in early diagnosis, the need for adjuvant therapy
for early cancer treatment and prevention of recurrence after surgery has
increased. Aston Sci. shifted our focus to meet such demand.” said The CEO of
Aston Sci., Hunwoo Shin, “We strive to increase the clinical value of cancer vaccines
through subsequent clinical trials and research, and also focus our
capabilities on future business development.”
In addition, Aston Sci. has 10 pipelines in various preclinical and
clinical stages including AST-301 and AST-021p. By 2030, the company plans to
expand its pipeline to 15 drugs in 4 clinical fields, focusing on efficient development
of new drugs with high unmet medical needs and high demand in clinical fields.
Aston Sci. decided to list on the KOSDAQ in order to facilitate its clinical
and business development, and as part of that, NH Investment & Securities
was selected as the listing manager in May. It is in the works, with the goal
to list in early 2023 upon receiving technology evaluation within the next
year.
About Aston Sci.
Aston Sci. Inc. is a portfolio model biopharmaceutical company. It is highly regarded in the industry for its active pipelines and portfolio composition that mainly focus on clinical development of innovative medicines in oncology, immunology, and geriatrics. Aston Sci. is headquartered in Seoul, South Korea, with a U.S. office in Washington.